Highest-materiality recent filing
Weight Watchers Q2 revenue $162.3M, clinical subscribers up 55.7% YoY; reaffirms FY guidance
Q2 revenue $162.3M (down 14% YoY); clinical subscription revenue $39.9M, up 30.4% YoY.
WW International shareholders elect all six director nominees at 2026 annual meeting
All six director nominees elected with >97% votes cast in favor: Davis, Gavales, Gove, Hawks, Sjoqvist, Thiltgen.
WW International settles with former CEO Tara Comonte for $1.85M
Settlement payment of $1,850,000 in two installments: $545,205.48 now, $1,304,794.52 by Oct 1, 2026.
Q1 revenue $168M, net loss $52M; adjusted EBITDA loss $1.8M vs prior adj EBITDA $26.9M (not comparable due to fresh start accounting).
Weight Watchers to use up to $40M to prepay term loan; reaffirms 2026 guidance
Company intends to prepay $25M-$30M of term loan (annual cash sweep) due June 24, 2026.
WW International appoints healthcare executive Heather Thiltgen to Board
Heather Thiltgen elected to Board effective April 20, 2026; Board expands to six members.
WW International director resigns; interim CEO compensation approved for CFO and COO
Director Michael Mason resigns effective April 13, 2026, for personal reasons; board size reduced from six to five.
Weight Watchers appoints new directors to committees; no interim CEO, continues Office of the CEO
Lisa Gavales appointed to Compensation & Benefits and Strategy & Finance committees; Sue Gove to Audit and Nominating & Governance committees.
Weight Watchers appoints Lisa Gavales and Sue Gove to board, expands to 6 members
Lisa Gavales (ex-Express CMO) and Sue Gove (ex-Bed Bath & Beyond CEO) elected independent directors effective April 7, 2026.
WW CEO Tara Comonte resigns; OCEO established; legal chief Cooke departs with $1.5M separation
CEO Tara Comonte resigned March 31, 2026; Board established Office of the CEO with CFO DellaFortuna and COO Volkmann effective April 3.
Weight Watchers Q4 rev $163M, net loss $6M; clinical subs up 42%; FY2026 rev guidance $620-635M
Q4 total revenue $163M (-12% YoY); net loss $6M vs income $25M YoY; adjusted EBITDA $18M (11.1% margin).
WW International grants PSUs, RSUs, and cash awards to executives; CFO salary raised to $600k
Tara Comonte receives 54,000 target PSUs, 120,000 RSUs, and $3.78M target cash award.
WeightWatchers Q3 net loss $58M, revenue $172M; narrows FY guidance to higher end
Total revenue $172M, down 10.8% YoY; clinical subscription revenue $26M, up 35.3% YoY.
WW International amends consulting agreement with former CPO Donna Boyer
Former CPO Donna Boyer entered second amendment to consulting agreement effective Sept 1, 2025.
WeightWatchers emerges from reorganization, cuts debt $1.15B; Q2 combined revenue down 6%
Completed strategic reorganization on June 24, reducing debt by $1.15 billion and applying fresh-start accounting.
Completed financial reorganization with enhanced flexibility; relisted on Nasdaq under ticker WW on July 8, 2025.
WW International exits Chapter 11; old equity canceled, $465M new term loan, new board
Emergence effective June 24, 2025; old common stock canceled, holders receive 900,000 of 10M new shares (9%).
Court confirmed prepackaged plan on June 17, 2025; exit expected on or about June 24, 2025.
WW International files amended Chapter 11 plan; existing equity to get 9% of new common
Amended Plan Supplement filed June 12: existing equity holders receive 9% of new common equity, subject to milestones; first lien holders get 91%.
WW International files amended Chapter 11 plan; takeback debt all term loans; stock delisted to OTC
Nasdaq delisting effective after Form 25; stock now trades OTC under WGHTQ since May 16.
Nasdaq notified WW on May 9, 2025, that its common stock will be delisted following the Chapter 11 filing on May 6.
Filed Chapter 11 on May 6, 2025 with prepackaged plan supported by 72% of First Lien Creditors.
WW Q1 revenue down 9.7% to $186.6M; clinical revenue up 57%; in debt restructuring talks
Net loss improved to $72.6M ($0.91 EPS loss) from $347.9M ($4.39) YoY.
WW International receives Nasdaq bid price deficiency notice; has 180 days to regain compliance
Received Nasdaq letter on March 19, 2025 for failure to maintain minimum $1.00 bid price.
WW International Q4 net income $25.1M vs loss; names Tara Comonte permanent CEO
Q4 revenue $184.4M (-10.5% YoY); subscription rev down 7.3%; clinical subscription rev $20.5M (+57.9%).
WW International borrows remaining $121.3M under revolver; total debt $175M
Borrowed $121.3M, the full remaining capacity under senior secured revolver on Jan 31, 2025.
WW International appoints Felicia DellaFortuna as CFO, replacing Heather Stark effective Jan 1, 2025
Heather Stark to cease as CFO on Dec 27, 2024; she receives $884,293 cash severance plus benefits, subject to release.
WW International Q3 revenue $192.9M, operating loss $39M; subscribers down 8.8%
Revenue $192.9M (-10.2% YoY); subscription revenue $191.2M (-6.0%).
WW CEO Sistani departs; board member Comonte appointed interim CEO; FY2024 guidance reaffirmed
Sistani steps down as CEO and director effective Sept 27; receives severance, transition services, coaching ($37.5k), and legal fees ($50k).
WeightWatchers Q2 revenue down 10.9% to $202.1M, announces $100M restructuring plan, CTO departs
Revenues $202.1M (down 10.9% YoY); net income $23.3M (down 54.2%); EPS $0.29 (down 54.9%).
WW International corrects 8-K: majority voting proposal rejected; Articles of Correction filed
Proposal 4 (majority director voting) failed: 28.7M for, 454.5K against, required majority of outstanding shares.
WW International CMO Amanda Tolleson to depart June 4; separation agreement includes $450K payment
Amanda Tolleson, Chief Marketing Officer, leaves WW International effective June 4, 2024.
Elected Denis Kelly & Julie Rice (Class II) and Tara Comonte & William Shrank (Class I) as directors.
WW International corrects Q1 subscriber metrics; Clinical subscribers overstated by 4k
Clinical End of Period Subscribers corrected to 87k from 91k; Total End of Period Subscribers to 4.004M from 4.008M.
WW Q1 2024: Revenue $206.5M, op loss $269.3M on $258M impairment; subscriber flat 4.0M
Revenue $206.5M (-14.6% YoY); subscription revenue $204.1M (-3.3%); other revenue $2.5M (-92%).
WW on track to beat Q1 fiscal 2024 guidance for Clinical subscribers
Company disclosed to employees it expects to exceed previously issued Q1 2024 guidance for end-of-period Clinical subscribers.
WW Q4 net loss $88.1M (-$1.11 EPS); Oprah Winfrey leaves board, donates stock
Q4 revenue $206.0M (down 7.6% YoY); net loss $88.1M vs $35.8M loss in prior year.
WW International General Counsel Michael Colosi to depart Dec 29; receives $897,657 lump-sum
Michael F. Colosi, General Counsel and Secretary, to depart Dec 29, 2023.
WW Q3 revenue $214.9M (-14% YoY); subscriber growth 6% to 4.0M; FY guidance narrowed
Revenue $214.9M (-14% YoY); subscription revenue $203.5M (-7.8%); product sales down 61%.
WW International names Nicole Haag Corporate Controller & PAO; Kossover resigns
Amy Kossover resigned as SVP, Corporate Controller and PAO effective Aug 23, 2023; leaves Sept 1.
WW International Q2 revenue falls 15.8% to $226.8M; subs grow sequentially
Q2 revenues $226.8M, down 15.8% YoY; operating income $26.3M vs $13.4M prior year.
WW International appoints Dr. William Shrank to board, replacing Jennifer Dulski
Jennifer Dulski resigns from board effective Aug 4, 2023; no disagreement with company.
8-K filing does not disclose a specific material event; data appears routine.
Filing consists primarily of XBRL financial statement tags for fiscal 2020-2022.
Weekend Health's 2022 revenue $6.28M (subscriptions $4.65M); net loss $17.46M ($15.1M from SAFE revaluation).
WW International appoints Tara Comonte to board; director Sobecki resigns after 24 years
Christopher Sobecki resigned as director effective May 31, 2023; no disagreement with the company.
WW International shareholders re-elect directors, approve say-on-pay frequency at annual meeting
Tracey D. Brown and Jennifer Dulski elected as Class I directors; 43.7M and 43.3M votes for respectively.
WW International reports Q1 operating loss of $28.6M, revenue falls 18.8% YoY
Q1 revenue $241.9M, down 18.8% YoY; operating loss $28.6M vs $9.0M profit last year.
WW International appoints Heather Stark as CFO effective May 4, 2023
Heather Stark appointed CFO; served as Interim Principal Financial Officer since Dec 2022 and Head of Finance, North America.
WW International CTO Michael Lysaght to depart June 2, 2023; Pierre-Olivier Latour named successor
Michael Lysaght, CTO, to leave WW International on June 2, 2023; receives 12 months base salary continuation and health coverage.
WW International completes $132M acquisition of telehealth platform Sequence
Total consideration $132M: ~$64.2M cash (incl. $25.8M of Sequence cash), ~$34.7M stock (8M shares at $4.34), plus $16M deferred on each of Apr 10, 2024 and 2025.
Tara Comonte, the Company’s former President and Chief Executive Officer, resigned from her position as President and Chief Executive Officer of the Company, effective March 31, 2026.
On November 27, 2024, WW International, Inc. (the “Company”) announced that it had mutually agreed with Heather Stark, Chief Financial Officer of the Company, that she would cease serving as the Company’s Chief Financial Officer, effective December 27, 2024
On November 27, 2024, the Company also announced the appointment of Felicia DellaFortuna to serve as its Chief Financial Officer, effective January 1, 2025
On September 26, 2024, the Board appointed Tara Comonte as Interim President and Chief Executive Officer, effective September 27, 2024, to serve until a permanent President and Chief Executive Officer is identified.
On September 26, 2024, WW International, Inc. (the “Company”) and Sima Sistani, the Company’s President and Chief Executive Officer, mutually agreed that Ms. Sistani would cease serving as the Company’s President and Chief Executive Officer, effective September 27, 2024.
the elimination of the position of Chief Technology Officer effective August 9, 2024 and the related departure from the Company of Pierre-Olivier Latour
On May 21, 2024, WW International, Inc. (the “Company”) announced that Amanda Tolleson, Chief Marketing Officer of the Company, would be leaving the Company on June 4, 2024 (the “Departure Date”).
On February 26, 2024, Oprah Winfrey notified the Chairman of the Company’s Board of Directors (the “Board”) that she would not be standing for re-election as a member of the Board at the Company’s 2024 annual meeting of shareholders.
On November 29, 2023, WW International, Inc. (the “Company”) announced that Michael F. Colosi, General Counsel and Secretary of the Company, would be leaving the Company on December 29, 2023 (the “Departure Date”).
Effective August 24, 2023, the Company appointed Nicole Haag, the Company’s Vice President, Internal Audit, as Corporate Controller and Principal Accounting Officer.
On August 23, 2023, WW International, Inc. (the “Company”) announced that effective as of 11:59 p.m. on that same date, Amy Kossover resigned as Senior Vice President, Corporate Controller and Principal Accounting Officer of the Company and will leave the Company on September 1, 2023.
On July 31, 2023, Jennifer Dulski notified the Secretary of WW International, Inc. (the “Company”) of her resignation as a director of the Company, effective as of 11:59 p.m. on August 4, 2023.
Max materiality 1.00 · Median 0.65 · Most common event leadership